Orient Biotech(SH:688298)2020-04-27 16:00Financial Performance - Net profit attributable to shareholders increased by 262.52% to CNY 43,916,037.42 year-on-year[10] - Operating income rose by 39.21% to CNY 110,363,284.73 compared to the same period last year[10] - Basic earnings per share increased by 184.62% to CNY 0.37 compared to the same period last year[10] - The company reported a net profit excluding non-recurring gains and losses of CNY 42,891,371.26, up 302.49% year-on-year[10] - Net profit surged by 301.48% to RMB 45,662,622.05 from RMB 11,373,533.86, attributed to increased sales of COVID-19 testing products[21] - Total operating revenue for Q1 2020 was $110.36 million, a 39.2% increase from $79.28 million in Q1 2019[44] - Operating profit for Q1 2020 was $53.54 million, significantly up from $12.05 million in Q1 2019, marking a growth of 344.5%[44] - Net profit for Q1 2020 reached $45.66 million, compared to $11.37 million in Q1 2019, an increase of 302.5%[46] - The total profit for Q1 2020 was $53.40 million, compared to $13.82 million in Q1 2019, an increase of 286.5%[46] - The company achieved a total comprehensive income of $45.99 million in Q1 2020, significantly higher than $10.83 million in Q1 2019, marking a growth of 325.5%[46] Assets and Liabilities - Total assets increased by 205.92% to CNY 1,105,937,924.13 compared to the end of the previous year[10] - The company's total equity attributable to shareholders increased by 236.39% to RMB 846,789,794.67 from RMB 251,728,329.24, reflecting the successful capital raise and profit growth[21] - Current liabilities rose to ¥239,172,948.82 compared to ¥91,516,969.01, indicating increased short-term financial obligations[32] - Total liabilities amounted to ¥255,003,326.54, up from ¥107,384,932.56, reflecting higher financial leverage[34] - Shareholders' equity increased to ¥850,934,597.59 from ¥254,126,547.51, demonstrating strong retained earnings growth[34] Cash Flow - Net cash flow from operating activities surged by 5,837.70% to CNY 143,151,308.57 year-to-date[10] - Cash inflow from operating activities totaled CNY 269,910,429.58, significantly higher than CNY 77,849,055.84 in the same quarter last year[54] - Cash outflow from investing activities was CNY 676,953,504.74, leading to a net cash flow from investing activities of -CNY 616,935,360.45[54] - Cash inflow from financing activities was CNY 578,898,359.62, while cash outflow was CNY 21,065,465.79, resulting in a net cash flow from financing activities of CNY 557,832,893.83[56] - The net increase in cash and cash equivalents was CNY 86,610,902.35, compared to a decrease of CNY 8,584,754.93 in the previous year[56] Shareholder Information - The total number of shareholders at the end of the reporting period was 13,623[16] - The top shareholder, Anji Fulanglai Import and Export Trade Co., Ltd., held 19.50% of the shares[16] Research and Development - The proportion of R&D investment to operating income decreased by 1.56 percentage points to 7.13%[10] - Research and development expenses increased to $7.87 million in Q1 2020 from $6.89 million in Q1 2019, a rise of 14.3%[44] Market Strategy - The company plans to continue expanding its market presence and product offerings, particularly in the field of COVID-19 related products[21] Other Financial Metrics - The weighted average return on equity increased by 0.99 percentage points to 6.85%[10] - The company reported a significant increase in inventory by 36.91% to RMB 106,740,136.03 from RMB 77,963,649.97, driven by increased orders[19] - The company reported a financial income of $3.12 million in Q1 2020, compared to a financial expense of $3.51 million in Q1 2019, indicating a turnaround[44] - Other comprehensive income after tax for Q1 2020 was $327,527.75, contrasting with a loss of $545,982.40 in Q1 2019[46]